Juno Therapeutics Inc.JUNO is expected to report fourth quarter 2014 results on Mar 18, 2015. Let's see how things are shaping up for this quarter.
Pipeline to be in Focus
This will be the first quarterly earnings release for Juno Therapeutics. The company's pipeline is expected to be in focus in the fourth quarter. The pipeline consists of several leukemia candidates including JCAR017, JCAR015 and JCAR014. These are all chimeric antigen receptor candidates.
JCAR015 is being developed for the treatment of adults suffering from acute lymphoblastic leukemia (ALL) in a phase I study. The candidate was granted both Breakthrough Therapy designation and Orphan Drug designation in the U.S. for this indication.
JCAR017 is in a phase I/II study being developed for the treatment of pediatric and young adults suffering from relapsed/refractory ALL. JCAR014 is also in phase I/II studies for the treatment of relapsed or refractory chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and ALL. We note there are several companies like Roche RHHBY that are marketing leukemia drugs.
We expect investor focus to remain on pipeline candidates going forward.
Our proven model does not conclusively show that Juno Therapeutics is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. This is not the case here, as you will see below.
Zacks ESP: The Earnings ESP for Juno Therapeutics is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate are at a loss of 33 cents per share.
Zacks Rank: Juno Therapeutics carries a Zacks Rank #3. Juno Therapeutics' Zacks Rank #3 when combined with an ESP of 0.00% makes surprise prediction difficult.
We caution against stocks with Zacks Ranks #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter:
Catalyst Pharmaceutical Partners Inc. CPRX has an earnings ESP of +14.29% and carries a Zacks Rank #3. It is expected to report fourth-quarter results on Mar 18.
uniQure N.V. QURE has an earnings ESP of +19.44% and carries a Zacks Rank #3. It is expected to report fourth-quarter results on Mar 25.